Literature DB >> 18600405

Primary biliary cirrhosis and osteoporosis: a case-control study.

Aziza Mounach1, Zhor Ouzzif, Ghizlane Wariaghli, Lahsen Achemlal, Imane Benbaghdadi, Aziz Aouragh, Ahmed Bezza, Abdellah El Maghraoui.   

Abstract

Osteoporosis is a common complication of chronic liver disease, from cholestatic disorders to autoimmune, alcoholic, and posthepatitic cirrhosis. Osteoporosis appears more striking in patients with primary biliary cirrhosis (PBC) because the disease usually affects elderly women, who are naturally prone to osteoporosis. Our aims were (1) to compare the prevalence of osteoporosis (T-score <-2.5 SD) between PBC patients and a group of age-and sex-matched controls consisting of healthy subjects from the general population; and (2) to identify the main risk factors for the development of bone loss. Thirty-three women with PBC (mean age, 47.3 +/- 10.4 years) and 66 healthy subjects were enrolled in the study. Bone mineral density (BMD) was assessed at the lumbar spine by dual-photon X-ray absorptiometry. Bone metabolism was evaluated by measuring serum calcium corrected for serum albumin, 25-hydroxyvitamin D (25-OH vit D), parathyroid hormone, and osteocalcin. Vertebral fractures were analyzed using vertebral fracture assessment (VFA). The mean T-score was lower in the PBC group compared to healthy controls, with a significant statistical difference (-2.39 +/- 0.93 and -1.47 +/- 0.99 in lumbar spine and total hip, respectively, in the PBC group versus -0.99 +/- 0.51 and -0.56 +/- 1.14 in healthy controls (P < 0.001). The prevalence of osteoporosis was 51.5% in the PBC group versus 22.7% in healthy controls with a statistically significant difference (P = 0.004). BMD of the PBC group was significantly correlated positively with body mass index (BMI) and 25-OH vit D, and negatively with menopausal status, duration of disease, and parathyroid hormone (PTH) levels. Vertebral fractures were present in 9% of the patients. We found that osteoporosis is more prevalent in women with PBC than in the general population. BMI, menopausal status, duration of the disease, and vitamin D deficiency are the main risk factors for osteoporosis in this liver disease.

Entities:  

Mesh:

Year:  2008        PMID: 18600405     DOI: 10.1007/s00774-007-0833-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  36 in total

1.  Does "hepatic osteodystrophy" differ from peri- and postmenopausal osteoporosis? A histomorphometric study.

Authors:  M S Shih; C Anderson
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

2.  Is osteoporosis a peculiar association with primary biliary cirrhosis?

Authors:  Annarosa Floreani; Andrea Mega; Valentina Camozzi; Vincenzo Baldo; Mario Plebani; Patrizia Burra; Giovanni Luisetto
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

3.  Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis.

Authors:  R Olsson; C Johansson; G Lindstedt; D Mellström
Journal:  Scand J Gastroenterol       Date:  1994-08       Impact factor: 2.423

4.  Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease.

Authors:  O M Crosbie; R Freaney; M J McKenna; J E Hegarty
Journal:  Calcif Tissue Int       Date:  1999-04       Impact factor: 4.333

5.  Body mass index and gynecological factors as determinants of bone mass in healthy Moroccan women.

Authors:  Abdellah El Maghraoui; Ahmed Anas Guerboub; Aziza Mounach; Imad Ghozlani; Abderrazak Nouijai; Mirieme Ghazi; Lahsen Achemlal; Ahmed Bezza; Mohamed Adnane Tazi
Journal:  Maturitas       Date:  2006-11-28       Impact factor: 4.342

Review 6.  Bone disease in cholestatic liver disease.

Authors:  J E Hay
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

7.  Osteoporosis: still a typical complication of primary biliary cirrhosis?

Authors:  E Solerio; G Isaia; R Innarella; M Di Stefano; M Farina; E Borghesio; L Framarin; M Rizzetto; F Rosina
Journal:  Dig Liver Dis       Date:  2003-05       Impact factor: 4.088

8.  Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia.

Authors:  J A Cuthbert; C Y Pak; J E Zerwekh; K D Glass; B Combes
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

9.  Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.

Authors:  C H Janes; E R Dickson; R Okazaki; S Bonde; A F McDonagh; B L Riggs
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?

Authors:  K D Lindor; C H Janes; J S Crippin; R A Jorgensen; E R Dickson
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  27 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

2.  An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis.

Authors:  L Caplan; A E Hines; E Williams; A V Prochazka; K G Saag; F Cunningham; E Hutt
Journal:  Osteoporos Int       Date:  2010-04-01       Impact factor: 4.507

3.  Immune complexes regulate bone metabolism through FcRγ signalling.

Authors:  Takako Negishi-Koga; Hans-Jürgen Gober; Eriko Sumiya; Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Ayako Suematsu; Tomomi Suda; Kojiro Sato; Toshiyuki Takai; Hiroshi Takayanagi
Journal:  Nat Commun       Date:  2015-03-31       Impact factor: 14.919

Review 4.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

5.  Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants.

Authors:  Brian D Juran; Gideon M Hirschfield; Pietro Invernizzi; Elizabeth J Atkinson; Yafang Li; Gang Xie; Roman Kosoy; Michael Ransom; Ye Sun; Ilaria Bianchi; Erik M Schlicht; Ana Lleo; Catalina Coltescu; Francesca Bernuzzi; Mauro Podda; Craig Lammert; Russell Shigeta; Landon L Chan; Tobias Balschun; Maurizio Marconi; Daniele Cusi; E Jenny Heathcote; Andrew L Mason; Robert P Myers; Piotr Milkiewicz; Joseph A Odin; Velimir A Luketic; Bruce R Bacon; Henry C Bodenheimer; Valentina Liakina; Catherine Vincent; Cynthia Levy; Andre Franke; Peter K Gregersen; Fabrizio Bossa; M Eric Gershwin; Mariza deAndrade; Christopher I Amos; Konstantinos N Lazaridis; Michael F Seldin; Katherine A Siminovitch
Journal:  Hum Mol Genet       Date:  2012-08-29       Impact factor: 6.150

6.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 7.  Osteodystrophy in chronic liver diseases.

Authors:  Pasquale Mansueto; Antonio Carroccio; Aurelio Seidita; Gaetana Di Fede; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2012-01-13       Impact factor: 3.397

8.  RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.

Authors:  Yan-Li Hao; Zhao-Lian Bian; Lin-Ling Ju; Yuan Liu; Gang Qin
Journal:  Dig Dis Sci       Date:  2019-08-03       Impact factor: 3.199

9.  Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.

Authors:  Sanne Skovgård Veidal; Efstathios Vassiliadis; Anne-Christine Bay-Jensen; Gervais Tougas; Ben Vainer; Morten Asser Karsdal
Journal:  Fibrogenesis Tissue Repair       Date:  2010-04-01

10.  Evidence of degraded BMD and geometry at the proximal femora in male patients with alcoholic liver cirrhosis.

Authors:  Dj Culafić; D Djonic; V Culafic-Vojinovic; S Ignjatovic; I Soldatovic; J Vasic; T J Beck; M Djuric
Journal:  Osteoporos Int       Date:  2014-08-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.